Integragen Stock

Integragen FCF Yield

The Free Cash Flow Yield of Integragen (ALINT.PA) as of Aug 3, 2026 is -128.58 %.

FCF Yield

-128.58 %

Last updated:

Free Cash Flow Yield of Integragen is 2026 -128.58 % . Free Cash Flow Yield of Integragen was 2025 0.00 . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

Integragen Stock analysis

What does Integragen do? IntegraGen SA is a French biotechnology company based in Evry. It was founded in 2000 and is one of the leading companies in developing commercial applications in genomics and biology. The business model of IntegraGen SA consists of providing solutions and services for the diagnosis and treatment of various diseases, such as cancer, neurodegenerative diseases, and other genetically related diseases. The company is divided into two main areas: Diagnostics and Genomics. The Diagnostics area offers a wide range of services to its customers, including an oncology platform for the diagnosis and prediction of cancer using exclusive biomarker sets. Other diagnostic tests are used for the identification of microorganisms in clinical samples and the detection of autoimmune diseases. In the Genomics area, the focus is on the development and sale of PCR kits for genotyping single nucleotide polymorphisms (SNPs) and analysis kits for RNA expression. These solutions allow for the identification and validation of genes in specific biological samples in a way that improves customers' understanding and enables accurate findings. IntegraGen SA is committed to continuously developing new tests and platforms to help its customers achieve more precise diagnoses and better therapies. One notable development of the company is the screening kit "Arisk," which is specifically designed for identifying genotypes that have an increased risk of colorectal cancer. The screening kit uses specific SNPs to ensure that doctors can identify patients who require increased monitoring or even prophylactic surgery. The use of genomics technology and biomarker-based diagnostics is a growing trend in medicine. IntegraGen SA plays a significant role in enabling the integration of genomics into clinical practice, ensuring the best possible diagnosis and treatment for patients. In summary, IntegraGen SA is an innovative biotechnology company dedicated to providing solutions for the diagnosis and prevention of diseases using various technologies. The company is constantly striving to develop new products and services to provide customers and partners with the best possible diagnostic and therapeutic support. Integragen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Integragen stock

Free Cash Flow Yield of Integragen is -128.58 % in 2026.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Integragen since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Integragen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Integragen

All Key Metrics — Integragen